Although CD19-targeted CAR T cell therapy effectively eliminates most autoantibodies against DNA and nucleosomal structures in SLE, certain autoantibodies, like those against Ro60 and Scl-70, persist (62). This evidence concerns the gene CD19 and systemic lupus erythematosus.